Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Operations: 2009-2024

Historic Cash from Operations for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to $4.9 million.

  • OptimizeRx's Cash from Operations rose 7878.28% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 12750.77%. This contributed to the annual value of $4.9 million for FY2024, which is 16752.76% up from last year.
  • Latest data reveals that OptimizeRx reported Cash from Operations of $4.9 million as of FY2024, which was up 16752.76% from -$7.2 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Cash from Operations ranged from a high of $10.7 million in FY2022 and a low of -$7.2 million during FY2023
  • For the 5-year period, OptimizeRx's Cash from Operations averaged around $543746.2, with its median value being $726039.0 (2021).
  • In the last 5 years, OptimizeRx's Cash from Operations tumbled by 27996.15% in 2020 and then surged by 136742.5% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's Cash from Operations stood at -$6.3 million in 2020, then surged by 111.51% to $726039.0 in 2021, then soared by 1367.43% to $10.7 million in 2022, then crashed by 167.96% to -$7.2 million in 2023, then soared by 167.53% to $4.9 million in 2024.
  • Its last three reported values are $4.9 million in FY2024, -$7.2 million for FY2023, and $10.7 million during FY2022.